Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview

References

• BriegerDFoxKAFitzgeraldGPredicting freedom from clinical events in non-ST-elevation acute coronary syndromes. The Global Registry of Acute Coronary EventsHeart2009
   Google Scholar
• AndersonHVShawREBrindisRGA contemporary overview of percutaneous coronary interventions. The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR)J Am Coll Cardiol20023971096110311923031
   PubMed Web of Science ®Google Scholar
• BrownJREdwardsFHO’ConnorGTRossCSFurnaryAPThe diabetic disadvantage: historical outcomes measures in diabetic patients undergoing cardiac surgery – the pre-intravenous insulin eraSemin Thorac Cardiovasc Surg200618428128817395023
   PubMedGoogle Scholar
• DonahoeSMStewartGCMcCabeCHDiabetes and mortality following acute coronary syndromesJAMA2007298776577517699010
   PubMed Web of Science ®Google Scholar
• MachecourtJDanchinNLablancheJMRisk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort RegistryJ Am Coll Cardiol200750650150817678732
   PubMed Web of Science ®Google Scholar
• SchaferABauersachsJEndothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosisCurr Vasc Pharmacol200861526018220940
   PubMed Web of Science ®Google Scholar
• MinaAFavaloroEJKouttsJHemostatic dysfunction associated with endocrine disorders as a major risk factor and cause of human morbidity and mortality: a comprehensive meta-reviewSemin Thromb Hemost200733879880918175285
   PubMed Web of Science ®Google Scholar
• NatarajanAZamanAGMarshallSMPlatelet hyperactivity in type 2 diabetes: role of antiplatelet agentsDiab Vasc Dis Res20085213814418537103
   PubMed Web of Science ®Google Scholar
• El HaouariMRosadoJAPlatelet signalling abnormalities in patients with type 2 diabetes mellitus: a reviewBlood Cells Mol Dis200841111912318387322
   PubMed Web of Science ®Google Scholar
• SudicDRazmaraMForslundMJiQHjemdahlPLiNHigh glucose levels enhance platelet activation: involvement of multiple mechanismsBr J Haematol2006133331532216643434
   PubMed Web of Science ®Google Scholar
• RajendranSChirkovYYPlatelet hyperaggregability: impaired responsiveness to nitric oxide (“platelet NO resistance”) as a therapeutic targetCardiovasc Drugs Ther200822319320318327704
   PubMed Web of Science ®Google Scholar
• AnfossiGRussoITrovatiMResistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndromeCurr Vasc Pharmacol20086431332818855719
   PubMed Web of Science ®Google Scholar
• CorradoECamardaPCoppolaGPrognostic role of endothelial dysfunction and carotid intima-media thickness in patients undergoing coronary stent implantationInt Angiol2009281121919190550
   PubMed Web of Science ®Google Scholar
• IraceCTschakovskyMECaralloCCorteseCGnassoAEndothelial dysfunction or dysfunctions? Identification of three different FMD responses in males with type 2 diabetesAtherosclerosis2008200243944518262189
   PubMed Web of Science ®Google Scholar
• MeigsJBMittlemanMANathanDMHyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring StudyJAMA2000283222122810634338
   PubMed Web of Science ®Google Scholar
• Juhan-VagueIAlessiMCVaguePThrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitusAnn Med19962843713808862693
   PubMed Web of Science ®Google Scholar
• SchneiderDJNordtTKSobelBEAttenuated fibrinolysis and accelerated atherogenesis in type II diabetic patientsDiabetes1993421178420806
   PubMed Web of Science ®Google Scholar
• McGillJBSchneiderDJArfkenCLLucoreCLSobelBEFactors responsible for impaired fibrinolysis in obese subjects and NIDDM patientsDiabetes19944311041098262307
   PubMed Web of Science ®Google Scholar
• NordtTKBodeCImpaired endogenous fibrinolysis in diabetes mellitus: mechanisms and therapeutic approachesSemin Thromb Hemost200026549550111129405
   PubMed Web of Science ®Google Scholar
• SerebruanyVLMalininAOngSAtarDPatients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular diseaseJ Thromb Thrombolysis200825220721317530178
   PubMed Web of Science ®Google Scholar
• SerebruanyVPokovIKuliczkowskiWChesebroJBadimonJBaseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery diseaseThromb Haemost20081001768218612541
   PubMed Web of Science ®Google Scholar
• SteinerMReinhardtKMKrammerBErnstBBlannADIncreased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic controlThromb Haemost19947269799847537916
   PubMed Web of Science ®Google Scholar
• MassuccoPMattielloLRussoIHigh glucose rapidly activates the nitric oxide/cyclic nucleotide pathway in human platelets via an osmotic mechanismThromb Haemost200593351752615735804
   PubMed Web of Science ®Google Scholar
• VarugheseGIPatelJVTomsonJBlannADHughesEALipGYPrognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in highrisk patients with hypertension: a sub-study of the Anglo-Scandinavian Cardiac Outcomes TrialJ Intern Med2007261438439117391113
   PubMed Web of Science ®Google Scholar
• HennVSlupskyJRGrafeMCD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cellsNature199839166675915949468137
   PubMed Web of Science ®Google Scholar
• DiMinnoGSilverMJCerboneAMMurphySTrial of repeated low-dose aspirin in diabetic angiopathyBlood19866848868913092890
   PubMed Web of Science ®Google Scholar
• SaccoMPellegriniFRoncaglioniMCAvanziniFTognoniGNicolucciAPrimary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trialDiabetes Care200326123264327214633812
   PubMed Web of Science ®Google Scholar
• OgawaHNakayamaMMorimotoTLow-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trialJAMA2008300182134214118997198
   PubMed Web of Science ®Google Scholar
• Collaborative overview of randomised trials of antiplatelet therapy – I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients Antiplatelet Trialists’ CollaborationBMJ19943086921811068298418
   PubMed Web of Science ®Google Scholar
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)CAPRIE Steering CommitteeLancet19963489038132913398918275
   PubMed Web of Science ®Google Scholar
• BhattDLMarsoSPHirschATRinglebPAHackeWTopolEJAmplified benefit of clopidogrel versus aspirin in patients with diabetes mellitusAm J Cardiol200290662562812231089
   PubMed Web of Science ®Google Scholar
• SerebruanyVLMalininAIPokovABarsnessGHanleyDFEffects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trialAm Heart J2008155193 e1718082496
   PubMedGoogle Scholar
• YusufSZhaoFMehtaSRChrolaviciusSTognoniGFoxKKEffects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevationN Engl J Med2001345749450211519503
   PubMed Web of Science ®Google Scholar
• RoffiMChewDPMukherjeeDPlatelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromesCirculation2001104232767277111733392
   PubMed Web of Science ®Google Scholar
• TakahashiSUshidaMKomineRIncreased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirinThromb Res2007119451752416793119
   PubMed Web of Science ®Google Scholar
• AngiolilloDJFernandez-OrtizABernardoEPlatelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatmentDiabetes20055482430243516046311
   PubMed Web of Science ®Google Scholar
• KrasopoulosGBristerSJBeattieWSBuchananMRAspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysisBMJ2008336763719519818202034
   PubMed Web of Science ®Google Scholar
• AngiolilloDJBernardoESabateMImpact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery diseaseJ Am Coll Cardiol200750161541154717936152
   PubMed Web of Science ®Google Scholar
• SibbingDBraunSMorathTPlatelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosisJ Am Coll Cardiol2009531084985619264241
   PubMed Web of Science ®Google Scholar
• BonelloLCamoin-JauLArquesSAdjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective studyJ Am Coll Cardiol200851141404141118387444
   PubMed Web of Science ®Google Scholar
• AntmanEMMorrowDAMcCabeCHEnoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarctionN Engl J Med2006354141477148816537665
   PubMed Web of Science ®Google Scholar
• PriceMJGRAVITAS InvestigatorsPrimary results of GRAVITASAHA Scientific Sessions: Late-Breaking Clinical TrialsNov. 17, 2010Chicago, IL
   Google Scholar
• BeckerRCMoliternoDJJenningsLKSafety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II studyLancet2009373966791992819286091
   PubMed Web of Science ®Google Scholar
• StoneGWMcLaurinBTCoxDABivalirudin for patients with acute coronary syndromesN Engl J Med2006355212203221617124018
   PubMed Web of Science ®Google Scholar
• SawJLincoffAMDeSmetWLack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudyJ Am Coll Cardiol20044461194119915364319
   PubMed Web of Science ®Google Scholar
• BittlJAStronyJBrinkerJATreatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction anginaHirulog Angioplasty Study InvestigatorsN Engl J Med1995333127647697643883
   PubMed Web of Science ®Google Scholar
• BittlJAComparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty. The Hirulog Angioplasty Study InvestigatorsAm Heart J19951303 Pt 26586657668214
   PubMed Web of Science ®Google Scholar
• LincoffAMBittlJAHarringtonRABivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trialJAMA2003289785386312588269
   PubMed Web of Science ®Google Scholar
• StoneGWWitzenbichlerBGuagliumiGBivalirudin during primary PCI in acute myocardial infarctionN Engl J Med2008358212218223018499566
   PubMed Web of Science ®Google Scholar
• WiviottSDTrenkDFrelingerALPrasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trialCirculation2007116252923293218056526
   PubMed Web of Science ®Google Scholar
• JakubowskiJAWintersKJNaganumaHWallentinLPrasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profileCardiovasc Drug Rev200725435737418078435
   PubMed Web of Science ®Google Scholar
• MegaJLCloseSLWiviottSDCytochrome p-450 polymorphisms and response to clopidogrelN Engl J Med2009360435436219106084
   PubMed Web of Science ®Google Scholar
• MegaJLCloseSLWiviottSDCytochrome P450 genetic polymorphisms and the response to prasugrel. Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomesCirculation2009
   PubMed Web of Science ®Google Scholar
• SibbingDMorathTStegherrJImpact of proton pump inhibitors on the antiplatelet effects of clopidogrelThromb Haemost2009101471471919350116
   PubMed Web of Science ®Google Scholar
• GurbelPALauWCTantryUSOmeprazole: a possible new candidate influencing the antiplatelet effect of clopidogrelJ Am Coll Cardiol200851326126318206733
   PubMed Web of Science ®Google Scholar
• ErlingeDVarenhorstCBraunOOPatients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivoJ Am Coll Cardiol200852241968197719055987
   PubMed Web of Science ®Google Scholar
• WallentinLVarenhorstCJamesSPrasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery diseaseEur Heart J2008291213018055486
   PubMed Web of Science ®Google Scholar
• BrandtJTPayneCDWiviottSDA comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formationAm Heart J2007153166 e91617174640
   PubMed Web of Science ®Google Scholar
• WiviottSDBraunwaldEMcCabeCHPrasugrel versus clopidogrel in patients with acute coronary syndromesN Engl J Med2007357202001201517982182
   PubMed Web of Science ®Google Scholar
• WiviottSDBraunwaldEAngiolilloDJGreater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38Circulation2008118161626163618757948
   PubMed Web of Science ®Google Scholar
• TothPPThe potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromesPostgrad Med20091211597219179814
   PubMed Web of Science ®Google Scholar
• AngiolilloDJFernandez-OrtizABernardoEPlatelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?J Invasive Cardiol200416416917415152138
   PubMedGoogle Scholar
• RinaldiMJKirtaneAJPianaRNClinical, procedural, and pharmacologic correlates of acute and subacute stent thrombosis: results of a multicenter case-control study with 145 thrombosis eventsAm Heart J2008155465466018371472
   PubMed Web of Science ®Google Scholar
• LotrionteMBiondi-ZoccaiGGAgostoniPMeta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary interventionAm J Cardiol200710081199120617920357
   PubMed Web of Science ®Google Scholar
• AngiolilloDJShoemakerSBDesaiBRandomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) studyCirculation2007115670871617261652
   PubMed Web of Science ®Google Scholar
• AngiolilloDJCapranzanoPDesaiBImpact of P2Y(12) Inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patientsThromb Res2009124331832219012950
   PubMed Web of Science ®Google Scholar
• AngiolilloDJCapranzanoPGotoSA randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 studyEur Heart J200829182202221118567918
   PubMed Web of Science ®Google Scholar
• LeeSWParkSWHongMKTriple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosisJ Am Coll Cardiol200546101833183716286167
   PubMed Web of Science ®Google Scholar
• HanYLiYWangSCilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled studyAm Heart J2009157473373919332203
   PubMed Web of Science ®Google Scholar
• AhnYJeongMHJeongJWRandomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients – clilostazol for diabetic patients in drug-eluting stent (CIDES) trialCirc J2008721353918159096
   PubMed Web of Science ®Google Scholar
• MardikarHMHiremathMSMoliternoDJOptimal platelet inhibition in patients undergoing PCI: data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) studyAm Heart J20071542344 e1517643586
   PubMed Web of Science ®Google Scholar
• MehtaSRYusufSPetersRJEffects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE studyLancet2001358928152753311520521
   PubMed Web of Science ®Google Scholar
• SteinhublSRBergerPBMannJT3rdEarly and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trialJAMA2002288192411242012435254
   PubMed Web of Science ®Google Scholar
• ChenZMJiangLXChenYPAddition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trialLancet200536694971607162116271642
   PubMed Web of Science ®Google Scholar
• BhattDLFoxKAHackeWClopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic eventsN Engl J Med2006354161706171716531616
   PubMed Web of Science ®Google Scholar
• BhattDLFlatherMDHackeWPatients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trialJ Am Coll Cardiol200749191982198817498584
   PubMed Web of Science ®Google Scholar
• MarkusHSDrosteDWKapsMDual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trialCirculation2005111172233224015851601
   PubMed Web of Science ®Google Scholar
• DienerHCBogousslavskyJBrassLMAspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trialLancet2004364943133133715276392
   PubMed Web of Science ®Google Scholar